Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

PACGEL

Financiado

Plasma-ACtivated hydroGEL: new frontiers solutions in cardiac regenerative medic...

Heart diseases represent the main leading cause of mortality in EU and other industrialized countries. The development of minimally-invasive therapies to treat cardiovascular injuries is the subject of intense investigation by the... ver más

31/03/2025

POLITO

173K€

Presupuesto del proyecto: 173K€

Líder del proyecto

POLITECNICO DI TORINO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 1 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-06-08

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

HORIZON-MSCA-2021-PF-01-01: MSCA Postdoctoral Fellowships 2021

I+D

Cerrada hace 3 años

0% 100%

1 Participantes

POLITO

172.75K€ | Lider

Proyectos interesantes

PID2021-125767OB-I00 PLATAFORMAS CONDUCTIVAS E INTERACTIVAS MULTIFUNCIONALES BASA... 315K€ Cerrado

RTI2018-101256-J-I00 HIDROGELES BIOCOMPATIBLES CON RIGIDEZ DINAMICAMENTE AJUSTABL... 190K€ Cerrado

BIOELECTRIC A Soft Bioelectric Implant from Droplet Networks 150K€ Cerrado

MAT2015-73656-JIN DESARROLLO DE HIDROGELES BIOMIMETICOS Y ANDAMIOS TISULARES P... 205K€ Cerrado

SAF2014-59892-R POTENCIAL DE LOS CARDIOMIOCITOS DERIVADOS DE CELULAS PLURIPO... 242K€ Cerrado

FIS2017-85954-R HIDROGELES MAGNETICOS SUPRAMOLECULARES PARA MEDICINA REGENER... 133K€ Cerrado

Últimas noticias

25-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 52 concesiones

25-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 1 concesiones

25-11-2024: FUNDACION-EOI En las últimas 48 horas el Organismo FUNDACION EOI ha otorgado 6 concesiones

Duración del proyecto: 33 meses Fecha Inicio: 2022-06-08
Fecha Fin: 2025-03-31

Líder del proyecto

POLITECNICO DI TORINO

TRL 4-5

Presupuesto del proyecto 173K€

Descripción del proyecto Heart diseases represent the main leading cause of mortality in EU and other industrialized countries. The development of minimally-invasive therapies to treat cardiovascular injuries is the subject of intense investigation by the cardiac regenerative medicine community. Moreover, in vitro models of human cardiac pathological tissues mimicking disease-specific oxidative conditions are demanded for understanding pathological mechanisms at different disease stages, and for the development and preclinical validation of novel therapies, at reduced costs and in compliance with 3Rs (Reduction, Refinement, Replacement) principle. PACGEL aims at the design of novel plasma jet-activated hydrogels based on biocompatible polymers, to be exploited as: (i) injectable stimulating systems to promote cardiac tissue regeneration and (ii) in vitro models of diseased cardiac tissue with tunable oxidative conditions. The biological effect will depend on the doses and types of reactive oxygen and nitrogen species encapsulated in the hydrogels, modulated by the plasma jet treatment parameters. The objectives are: (1) to identify the minimal reactive species concentration (threshold limit) above which oxidative effects prevail, by in vitro tests with relevant human cardiac cells; 2) to develop plasma jet-activated hydrogels with regenerative potential; 3) to design in vitro 3D bio-printed tissue models mimicking different stages of human cardiac diseases. My expertise in Plasma Medicine and Chemistry, the supervisor’s consolidated competence in biomaterials design, tissue engineering and cardiac regenerative medicine, my proof-of-concept preliminary results and the availability of all the needed facilities and training opportunities at the Host Institution will ensure the research progress. Furthermore, PACGEL will address one major societal challenge such as the treatment of age-related cardiac diseases exploiting green technologies, thus achieving still a greater impact on society.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores